Stockreport

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024 [Yahoo! Finance]

Palatin Technologies, Inc.  (PTN) 
NASDAQ:AMEX Investor Relations: palatin.com/investors/overview
PDF Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P Rapid Onset of Efficacy at the 2-Week Treatment Period , Multiple Symptom Endpoints, Including the [Read more]